Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy
Authors: Nelson Leung, Sundararaman Swaminathan, Iftikhar Ahmed, James T. McCarthy, Robert C. Albright, Mark R. Pittelkow, Noel M. Caplice, Matthew D. Griffin
Journal: Annals of Internal Medicine (2007)

Letters6 February 2007Erythropoietin, Gadolinium, and Nephrogenic Fibrosing DermopathyNelson Leung, MD, Sundararaman Swaminathan, MBBS, Iftikhar Ahmed, MD, James T. McCarthy, MD, Robert C. Albright, DO, Mark R. Pittelkow, MD, Noel M. Caplice, MD, PhD, and Matthew D. Griffin, MB BChNelson Leung, MDFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, Sundararaman Swaminathan, MBBSFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, Iftikhar Ahmed, MDFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, James T. McCarthy, MDFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, Robert C. Albright, DOFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, Mark R. Pittelkow, MDFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, Noel M. Caplice, MD, PhDFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this author, and Matthew D. Griffin, MB BChFrom Mayo Clinic College of Medicine, Rochester, Minnesota.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-146-3-200702060-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We appreciate Dr. Hellman's interest and comments. We, too, have noted that nearly half of our patients with nephrogenic fibrosing dermopathy had gadolinium exposure before the development of their disease. However, a similar number of our 50 dialysis patients were also exposed to gadolinium—some exposed on several occasions—without any evidence of the condition. This seems to support our hypothesis that multiple factors are involved in the pathogenesis of nephrogenic fibrosing dermopathy. We are currently investigating the possible interaction between gadolinium and erythropoietin in this disease.Nelson Leung, MDSundararaman Swaminathan, MBBSIftikhar Ahmed, MDJames T. McCarthy, MDRobert C. Albright, DOMark ... Author, Article, and Disclosure InformationAffiliations: From Mayo Clinic College of Medicine, Rochester, Minnesota.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoNephrogenic Fibrosing Dermopathy and High-Dose Erythropoietin Therapy Sundararaman Swaminathan , Iftikhar Ahmed , James T. McCarthy , Robert C. Albright , Mark R. Pittelkow , Noel M. Caplice , Matthew D. Griffin , and Nelson Leung Erythropoietin, Gadolinium, and Nephrogenic Fibrosing Dermopathy Richard N. Hellman Metrics Cited BySurgical treatment for coronary artery aneurysm: a single-centre experienceGadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failureThe Role of the Hospital Dermatologist in the Diagnosis and Treatment of Calciphylaxis and Nephrogenic Systemic Fibrosis 6 February 2007Volume 146, Issue 3Page: 230KeywordsConflicts of interestErythropoietinMedical dialysisPathogenesis ePublished: 6 February 2007 Issue Published: 6 February 2007 CopyrightCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...